Healthy
Conditions
Interventions
Placebo:40mg po tid of placebo for two week, on the 15th day a single dose of fexofenadine120mg or midazolam 7.5mg or losartan potassium 50mg is given to volunteers
Breviscapine:40mg po tid of breviscapine for two week, on the 15th day a single dose of fexofenadine120mg or midazolam 7.5mg or losartan potassium 50mg is given to volunteers
Sponsors
College of Pharmacy and Chemistry, Dali University
Eligibility
Sex/Gender
All
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: 1. Healthy subjects aged 18 and 30 years; 2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 45 kg; 3. Without major disease history and history of drug allergy; 4. Non-drug,smoke and alcohol abuser; 5. All volunteers were not allowed to take any medications 2 wk before the study period; 6. Volunteers can communicate well with investigator and obey the rules of the study; 7. All volunteers gave their written informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects who paticipated in other clinical trials within the past 2 month; 2. Subjects who donated blood within the past 1 mo or will donate blood during or after the study; 3. Subjects who do not pass the general physical examinations and BP, HR or breath status are not well; 4. Subjects who have significant clinical symptoms by physical examination; 5. Subjects who have some health problems by electrocardiogram and laboratory tests (including complete blood count, blood biochemistry testing and urinalysis) before starting this study; 6. Invesigator thinks that the subjects are not suitable for participating the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The plasma concentrations of fexofenadine;The plasma concentrations of losartan and E3174;The plasma concentrations of midazolam and 1-OH midazolam; | — |
Countries
China
Contacts
Public ContactLai Yong
College of Pharmacy and Chemistry, Dali University
Outcome results
None listed